An Open Label, Double-blind Discontinuation Study of Quetiapine Extended Release(XR)

Inclusion Criteria: * Adults 18-65 years of age * A primary diagnosis of SAD,using Diagnostic Standard Manual IV(DSM-IV) criteria * Minimum CGI severity score of 4 and minimum Brief Social Phobia Scale (BSPS) score of 20 at baseline * Written informed consent * A negative serum pregnancy test for women of childbearing potential. Exclusion Criteria: * Current DSM-IV diagnosis of bipolar disorder, schizophrenia or other psychotic disorder, mental retardation or other pervasive developmental disorder, or cognitive disorder due to a general medical condition * Any current primary anxiety disorder other than SAD or current primary depression * History of substance abuse or dependence within the last 6 months * Suicide risk or serious suicide attempt within the last year * Clinically significant medical condition or laboratory abnormality * Women of childbearing potential who are unwilling to practice an acceptable method of contraception * Subjects needing concurrent use of psychotropic medications * History of hypersensitivity to quetiapine * History of cataracts.